ISAL 2019 | Updates in AML research from MD Anderson: novel venetoclax combinations with Naval
Naval Daver
• 14 Mar 2019
Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the leukemia research going on at his institute. He highlights research into the combination of venetoclax with tyrosine kinase or MDM2 inhibitors in acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
